Marvel Biosciences Announces Grant of Deferred Share Units
Marvel Biosciences (TSXV: MRVL) has granted 142,987 deferred share units (DSUs) to two directors as compensation in lieu of cash directors' fees. The DSUs are valued at $0.16 per unit based on the Volume Weighted Average Price (VWAP) of Marvel's common shares on the TSX Venture Exchange as of July 31, 2025.
The DSUs will vest on July 31, 2026 and will be settled upon the directors' separation from service, with an expiration period of 365 days after their departure.
Marvel Biosciences (TSXV: MRVL) ha concesso a due amministratori 142.987 unità differite di azioni (DSU) come compenso in luogo dei compensi in contanti. Le DSU sono valutate $0,16 per unità, in base al prezzo medio ponderato per il volume (VWAP) delle azioni ordinarie di Marvel sul TSX Venture Exchange al 31 luglio 2025.
Le DSU matureranno il 31 luglio 2026 e saranno liquidate alla cessazione del servizio dei direttori; le unità scadranno entro 365 giorni dalla loro uscita.
Marvel Biosciences (TSXV: MRVL) ha otorgado a dos directores 142.987 unidades diferidas de acciones (DSU) como compensación en lugar de honorarios en efectivo. Las DSU se valoran en $0,16 por unidad, según el precio medio ponderado por volumen (VWAP) de las acciones ordinarias de Marvel en la TSX Venture Exchange al 31 de julio de 2025.
Las DSU se consolidarán el 31 de julio de 2026 y se abonarán al cesar los directores en su cargo; tendrán un vencimiento de 365 días tras su salida.
Marvel Biosciences (TSXV: MRVL)는 현금 이사 보수 대신 보상으로 두 명의 이사에게 142,987 이연 주식 단위(DSU)를 부여했습니다. DSU는 2025년 7월 31일 기준 TSX 벤처 거래소에서 Marvel 보통주의 거래량가중평균가격(VWAP)에 따라 단위당 $0.16로 평가됩니다.
DSU는 2026년 7월 31일에 권리가 확정되며, 이사 퇴임 시 정산되고 퇴임 후 365일 이내에 만료됩니다.
Marvel Biosciences (TSXV: MRVL) a attribué à deux administrateurs 142 987 unités d'actions différées (DSU) en remplacement des honoraires en espèces. Les DSU sont évaluées à 0,16 $ par unité, d'après le cours moyen pondéré par les volumes (VWAP) des actions ordinaires de Marvel à la TSX Venture Exchange au 31 juillet 2025.
Les DSU deviendront acquises le 31 juillet 2026 et seront réglées lors du départ des administrateurs ; elles expireront 365 jours après leur départ.
Marvel Biosciences (TSXV: MRVL) hat zwei Direktoren 142.987 aufgeschobene Aktieneinheiten (DSUs) als Vergütung anstelle von Barauszahlungen gewährt. Die DSUs sind mit $0,16 pro Einheit bewertet, basierend auf dem volumengewichteten Durchschnittspreis (VWAP) der Stammaktien von Marvel an der TSX Venture Exchange zum 31. Juli 2025.
Die DSUs werden am 31. Juli 2026 unverfallbar und werden bei Ausscheiden der Direktoren ausgezahlt; sie verfallen 365 Tage nach dem Ausscheiden.
- None.
- None.
Calgary, Alberta--(Newsfile Corp. - August 11, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 142,987 deferred share units ("DSUs") to two of Marvel's directors, in lieu of cash payment for directors' fees.
The DSUs will all vest on July 31, 2026. Vested DSUs shall be settled upon the directors' separation from service from the Company and expire 365 days after such directors' separation from service.
The deemed value for the DSUs is calculated using the VWAP of the Company's Common Shares on the TSX Venture Exchange on July 31, 2025, being
About Marvel Biosciences Corp.
Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company. The Company is developing MB-204, a novel fluorinated derivative of the approved anti-Parkinson's drug Istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer's Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.
Contact Information:
Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262045
FAQ
What is the value of Marvel Biosciences' DSU grant to directors?
When will Marvel Biosciences' DSUs vest?
How long do Marvel Biosciences' DSUs remain valid after a director leaves?
How many directors received DSUs from Marvel Biosciences?
